Artiva Biotherapeutics, Inc.
ARTV Nasdaq
SEC CIK 1817241
Follow Artiva Biotherapeutics
Weekly email: filings, results
Net income
−$28.8M
−33.9% vs same quarter last year
EPS, diluted
−$0.56
+36.4% vs same quarter last year
Operating cash flow
−$28.4M
−48.2% vs same quarter last year
Operating income
−$32M
−39.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $0 | −$83.9M |
| FY24 | $251K | −$65.4M |
| FY23 | $32.9M | −$28.7M |
| FY22 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$79.3M |
| FY24 | −$55.7M |
| FY23 | −$50.7M |
| FY22 | - |